Eli Lilly and Novo Nordisk will kick off a massive shopping spree in 2025. The two obesity giants will be sitting on cash ...

Results of the study indicate that Black women in the U.S., ages 66-75, saw the largest decrease in obesity between 2022-2023 ...

In a public health breakthrough, U.S. obesity rates have decreased for the first time in more than a decade, with new weight ...

Brownstein and his team noted that women and adults aged 66 to 75 saw the largest decreases in obesity. People living in the ...

The secret agent in the decrease might be semaglutide, a GLP-1 receptor agonist that fuels popular weight loss drugs like ...

Altimmune is redefining success in both obesity and MASH to position Pemvidutide in blue ocean categories. Read why I rate ...

Obesity dipped slightly in U.S. adults last year, research found — the first time in more than a decade that the country has ...

A new study reveals that modulating endocannabinoids in the brain can reduce food intake and boost physical activity, ...

Obesity prevalence in the US decreased in 2023, with significant drops in the South, highlighting the impact of GLP-1RA ...

A new study published in the JAMA Health Forum found that obesity rates dropped from 46% in 2022 to 45.6% in 2023. The study ...

If coverage is structured properly, it could greatly help our country's chronic disease and obesity epidemics. But Donald Trump's Food and Drug Administration (FDA) will also need to ensure the drugs ...

Endocannabinoids in the brain play a key role in food intake and energy use. Modulating the action of these molecules could help fight obesity, say researchers.